Vifor Pharma (VIFN.SW) Stock Price
Vifor Pharma Price
Revenue at Vifor Pharma has contracted by 1.2% per year over the past 19 years to 1.82 B CHF. Earnings per share have grown at 5.4% per year over the last 19 years. For Vifor Pharma, the net margin of 7.9% is down versus 85.5% a few years ago. At today's price the dividend yield works out to roughly 1.20%. The payout ratio is around 81% of earnings.
Vifor Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Vifor Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vifor Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vifor Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Vifor Pharma Price |
|---|
Vifor Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Vifor Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB CHF |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB CHF |
| EBITM CHF |
| EBIT MARGIN% |
| NET INCOMEB CHF |
| NET INCOME GROWTH% |
| DIVIDENDDIV.CHF |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.19 | 3.29 | 3.36 | 3.42 | 3.79 | 4.12 | 1.34 | 1.58 | 1.88 | 1.71 | 1.82 | 1.86 | 2.08 | 2.42 | 2.71 | 3.00 |
| 2.67 | 3.36 | 1.97 | 1.70 | 10.98 | 8.63 | -67.41 | 18.03 | 18.50 | -9.16 | 6.98 | 2.08 | 11.60 | 16.65 | 11.84 | 10.59 |
| 33.70 | 35.06 | 35.40 | 36.24 | 38.54 | 39.80 | 61.40 | 59.09 | 59.40 | 58.89 | 63.16 | 63.16 | 63.16 | 63.16 | 63.16 | 63.16 |
| 1.07 | 1.16 | 1.19 | 1.24 | 1.46 | 1.64 | 0.82 | 0.94 | 1.12 | 1.00 | 1.15 | 1.18 | 1.31 | 1.53 | 1.71 | 1.89 |
| 327.00 | 337.00 | 383.00 | 360.00 | 445.00 | 356.00 | 134.00 | 184.00 | 325.00 | 266.00 | 422.00 | 408.00 | 468.00 | 543.00 | 801.00 | 948.00 |
| 10.26 | 10.23 | 11.40 | 10.54 | 11.74 | 8.64 | 9.99 | 11.62 | 17.31 | 15.60 | 23.14 | 21.91 | 22.52 | 22.40 | 29.55 | 31.62 |
| 0.26 | 0.25 | 0.30 | 0.28 | 0.30 | 0.24 | 1.15 | 0.15 | 0.16 | 0.36 | 0.14 | 0.24 | 0.28 | 0.33 | 0.58 | 0.69 |
| 9.91 | -0.78 | 17.00 | -4.05 | 5.99 | -19.27 | 372.02 | -86.75 | 4.61 | 125.79 | -59.89 | 63.19 | 17.02 | 18.55 | 78.83 | 18.70 |
| – | – | – | – | – | – | – | – | – | – | – | 2.00 | – | – | – | – |
| 64.93 | 64.91 | 64.88 | 64.91 | 64.87 | 64.92 | 65.02 | 65.05 | 64.89 | 64.86 | 58.53 | 58.53 | 58.53 | 58.53 | 58.53 | 58.53 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Vifor Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vifor Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vifor Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Vifor Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vifor Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Vifor Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Vifor Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Vifor Pharma business model & stock analysis
Vifor Pharma SWOT Analysis
Strengths
- Strong brand recognition in the pharmaceutical industry.
- Diversified product portfolio with a focus on innovative pharmaceuticals.
- Well-established distribution network and partnerships.
Weaknesses
- Limited global presence compared to competitors.
- Dependence on a few key products for revenue generation.
- Relatively small research and development budget.
Opportunities
- Growing global demand for pharmaceutical products, especially in emerging markets.
- Potential for strategic partnerships and collaborations to expand market reach.
- Increasing focus on personalized medicine and targeted therapies.
Threats
- Intense competition from both established pharmaceutical companies and generic drug manufacturers.
- Stringent regulatory requirements and increasing pricing pressures.
- Risk of patent expirations and generic competition.
Vifor Pharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Vifor Pharma historical P/E ratio, EBIT multiple, and P/S ratio
Vifor Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Vifor Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Vifor Pharma Dividend History
20 years of dividend payments
Vifor Pharma dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Vifor Pharma Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 3/1/2021 | Upgrade | SellNeutral | 51 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Vifor Pharma Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/5/2021 | 1.94CHF | - | 904.74 MCHF | - | 2021 Q2 |
| 3/3/2021 | 2.49CHF | - | 913.93 MCHF | - | 2020 Q4 |
| 8/6/2020 | 2.54CHF | - | 986.36 MCHF | - | 2020 Q2 |
| 3/12/2020 | 1.98CHF | - | 973.44 MCHF | - | 2019 Q4 |
| 8/8/2019 | 2.29CHF | - | 909.55 MCHF | - | 2019 Q2 |
| 3/14/2019 | 1.15CHF | - | 824.69 MCHF | - | 2018 Q4 |
| 8/8/2018 | 1.32CHF | - | 780.87 MCHF | - | 2018 Q2 |
| 3/15/2018 | 1.02CHF | - | 701.36 MCHF | - | 2017 Q4 |
| 8/8/2017 | -CHF | - | 628.79 MCHF | - | 2017 Q2 |
| 3/14/2017 | 1.73CHF | - | 2.11 BCHF | - | 2016 Q4 |
Vifor Pharma shareholder structure
| % | Name |
|---|---|
0.20828% | |
0.20263% | |
0.05772% | |
0.03288% | |
0.02306% | |
0.01230% |
Vifor Pharma Executives and Management Board
15 members · avg. age 56 · 27 % women
Mr. Abbas Hussain (57)
Chief Executive Officer
2.10 M CHF
Management
Mr. Michael Puri (52)
Chief Human Resource Officer, Member of the Executive Committee
Ms. Barbara Angehrn (46)
Chief Business Officer, Member of the Executive Committee
Mr. Herve Gisserot
Member of the Executive Committee, Chief Commercial Officer
Dr. Klaus Jensen (48)
Chief Medical Officer, Member of the Executive Committee
Dr. Christoph Springer (53)
Chief Strategy Officer, Member of the Executive Committee
Mr. Julien Vignot
Head Investor Relations · since 2015
Board of Directors
Mr. Jacques Theurillat (62)
Independent Chairman of the Board of Directors
Dr. Romeo Cerutti (59)
Independent Vice Chairman of the Board
Dr. Sue Mahony (56)
Independent Directors
Prof. Dr. Michel Burnier (67)
Independent Directors
Ms. Kim Stratton (58)
Independent Director
Ms. Asa Riisberg (48)
Independent Director
Vifor Pharma Supply Chain
Vifor Pharma Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.12 | 0.71 | 0.68 | ||
| 2 | 0.05 | 0.32 | 0.48 | ||
| 3 | 0.31 | 0.56 | 0.41 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Angion Biomedica | -0.82 | -0.76 | — | |
| 2 | American Renal Associates Holdings Inc | 0.50 | — | — | |
| 3 | -0.49 | -0.77 | -0.49 | ||
| 4 | CARA Therapeutics | -0.45 | -0.74 | -0.48 | |
| 5 | 0.42 | -0.66 | -0.47 |
Frequently asked questions about Vifor Pharma
The business model of Vifor Pharma AG focuses on the development, production, and commercialization of pharmaceutical products. As a global healthcare company, Vifor Pharma AG specializes in the field of iron deficiency, nephrology, and cardio-renal therapies. They aim to improve the quality of life for patients suffering from various medical conditions, including chronic kidney disease, iron deficiency anemia, and renal diseases. Vifor Pharma AG collaborates with healthcare professionals and organizations worldwide to bring innovative and effective treatments to market. By leveraging their expertise and research capabilities, Vifor Pharma AG continues to drive advancements in the field of pharmaceuticals and improve patient outcomes.
Vifor Pharma AG is primarily active in the pharmaceutical industry.
The main competitors of Vifor Pharma AG in the market include companies like Novartis, Roche, Sanofi, and AstraZeneca. These companies operate in similar therapeutic areas and engage in the development and commercialization of pharmaceutical products. Vifor Pharma AG competes with these companies through its innovative and high-quality offerings, strategic partnerships, and strong market presence. By continuously adapting and expanding its product portfolio, Vifor Pharma AG aims to maintain its competitive position within the pharmaceutical industry.
Vifor Pharma AG, a leading global pharmaceutical company, has a rich history and background. Established in 1872 and headquartered in Switzerland, Vifor Pharma focuses on innovative treatments for patients suffering from iron deficiency, nephrology, and cardio-renal disorders. The company has played a pivotal role in healthcare advancements, leveraging its expertise to develop high-quality and effective pharmaceutical products. Vifor Pharma operates globally, collaborating with healthcare professionals to improve patients' well-being. Committed to research, development, and sustainable growth, Vifor Pharma aims to enhance the lives of individuals worldwide through its innovative solutions in the medical field.
Vifor Pharma AG, a renowned pharmaceutical company, has achieved several significant milestones throughout its existence. Notably, it successfully developed and launched a groundbreaking medication for the treatment of iron deficiency anemia (IDA) called Ferinject®. This innovative intravenous iron replacement therapy has transformed patient care worldwide. Vifor Pharma AG has also made strides in the field of nephrology, advancing the treatment of chronic kidney disease (CKD) and associated complications. With a strong focus on research and development, Vifor Pharma AG continues to seek out new therapeutic options and strategic partnerships to further enhance patient outcomes and improve global healthcare.
Vifor Pharma AG is primarily present in various countries and regions worldwide. Its presence can be seen in Europe, North America, and certain parts of Asia. The company operates in diverse markets, including Switzerland, Germany, Austria, France, the United Kingdom, the United States, China, and Japan. With a global reach, Vifor Pharma AG has established itself as a leading pharmaceutical player in these regions, offering innovative healthcare solutions and improving patient outcomes.
Vifor Pharma AG represents a set of core values and corporate philosophy that guides its operations. The company's values include a strong commitment to patients, healthcare providers, and employees. Vifor Pharma AG strives to make a positive impact on patients' lives through innovative healthcare solutions. The company's corporate philosophy centers around trust, integrity, and excellence. Vifor Pharma AG focuses on continuous improvement and delivering value to its stakeholders. With a patient-centric approach, Vifor Pharma AG aims to enhance patient outcomes and drive sustainable growth in the pharmaceutical industry.
11 analysts currently rate the Vifor Pharma stock: 0 recommend buying, 4 holding and 7 selling.
Converted at the current exchange rate, the Vifor Pharma share trades at 176.67 EUR (166.15 CHF).
The Vifor Pharma share (VIFN.SW) is listed on 5 stock exchanges, including: Frankfurt (G2AA.F), München (G2AA.MU), Düsseldorf (G2AA.DU), London (0RPD.L), SIX (Zürich) (VIFN.SW).
Vifor Pharma AG is a Swiss pharmaceutical company specializing in the research, development, and marketing of medicines for patients with kidney diseases, iron deficiency anemia, and other important therapeutic areas. The company operates various divisions worldwide and is a leading provider of products in the healthcare industry.
The revenue cannot currently be calculated for Vifor Pharma.
The profit cannot currently be calculated for Vifor Pharma.
The P/E ratio cannot be calculated for Vifor Pharma at the moment.
The P/S cannot be calculated for Vifor Pharma currently.
The Eulerpool Quality Score for Vifor Pharma is 3/10.
The ISIN of Vifor Pharma is CH0364749348. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Vifor Pharma is A2DRZ4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Vifor Pharma is VIFN.SW. The ticker symbol is used to trade Vifor Pharma shares on the stock exchange.
The current dividend yield of Vifor Pharma is 1.20 %.
Vifor Pharma pays a dividend, distributed in the months of , , , .
Vifor Pharma paid dividends every year for the past 0 years.
Vifor Pharma is assigned to the 'Health' sector.
To receive the latest dividend of Vifor Pharma from amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Vifor Pharma are distributed in CHF.
Vifor Pharma stock
Vifor Pharma Peer Group
Vifor Pharma Ticker
Vifor Pharma FIGI
All fundamentals and in-depth analysis of Vifor Pharma
Our stock analysis for Vifor Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vifor Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.